The relative expression of AURKA and AURKB genes, by adopting the mean value from ΔCt, identified two distinct subgroups of CML patients, based on clinical and cytogenetic evidence. This evidence concerns the gene AURKB and chronic myelogenous leukemia, BCR-ABL1 positive.